Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio Aquiles

Marín-Jiménez, Ignacio; Sánchez, V. García; Gisbert, Javier P.; Calle, José Lázaro Pérez; Luján, M; Ábalos, Jordi Gordillo; Tabernero, Susana; Juliá, Berta; Romero, Cristina; Cea‐Calvo, Luis; García‐Vicuña, Rosario; Vanaclocha, F.

doi:10.1016/j.gastrohep.2014.02.010

Cited by 10 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persons with IBD had significantly increased odds pertaining to the development of asthma [odds ratio; OR 1.5, 95% confidence interval (CI) 1.4–1.6], psoriasis (OR 1.7, 95% CI 1.5–2.0), RA (OR 1.9, 95% CI 1.5–2.3), and MS (OR 2.3 95% CI 1.6–3.3). These results have been corroborated by other studies that add further credence to the validity of the phenomenon of IMID co-occurrence ( Bernstein et al, 2001b , 2005 ; Cucino and Sonnenberg, 2001 ; Cohen et al, 2008 ; Marin-Jiminez et al, 2014 ; Vanaclocha et al, 2015 ).…”

Section: Immune-mediated Inflammatory Disease Comorbiditysupporting

confidence: 83%

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

2016

View full text Add to dashboard Cite

The collection of microbes and their genes that exist within and on the human body, collectively known as the microbiome has emerged as a principal factor in human health and disease. Humans and microbes have established a symbiotic association over time, and perturbations in this association have been linked to several immune-mediated inflammatory diseases (IMID) including inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. IMID is a term used to describe a group of chronic, highly disabling diseases that affect different organ systems. Though a cornerstone commonality between IMID is the idiopathic nature of disease, a considerable portion of their pathobiology overlaps including epidemiological co-occurrence, genetic susceptibility loci and environmental risk factors. At present, it is clear that persons with an IMID are at an increased risk for developing comorbidities, including additional IMID. Advancements in sequencing technologies and a parallel explosion of 16S rDNA and metagenomics community profiling studies have allowed for the characterization of microbiomes throughout the human body including the gut, in a myriad of human diseases and in health. The main challenge now is to determine if alterations of gut flora are common between IMID or, if particular changes in the gut community are in fact specific to a single disease. Herein, we review and discuss the relationships between the gut microbiota and IMID.

show abstract

Section: Immune-mediated Inflammatory Disease Comorbiditysupporting

confidence: 83%

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

2016

View full text Add to dashboard Cite

show abstract

“…UC is typically diagnosed in early adulthood and clinically characterized by relapsing and remitting symptoms such as diarrhea, rectal bleeding, abdominal pain, fecal urgency, weight loss, and fatigue; in up to one third of patients, these symptoms are accompanied by articular, dermatological, and/or ocular diseases. 1 , 2 Although most UC patients present with a mild-to-moderate disease course, about 14%–17% of patients may experience an aggressive course. 3 These patients may require hospital admission, and up to 19% of patients with pancolitis will need colectomy, typically during the first 2 years after diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain

Calvet

Argüelles-Arias

López-Sanromán

et al. 2018

PPA

Self Cite

View full text Add to dashboard Cite

PurposeUlcerative colitis (UC) may cause many patients to miss out on important personal and professional opportunities. We therefore conducted a survey (UC-LIFE) to assess patients’ perceptions of the impact of UC on social and professional lives.Patients and methodsConsecutive unselected UC patients aged ≥18 years were recruited from 38 outpatient clinics in Spain. Patients completed the survey at home, returning it by post. The survey comprised 44 multiple-choice questions, including questions about the impact of UC on social, personal, professional, and academic activities.ResultsOf 585 patients invited, 436 (75%) returned the survey (mean age 46 years; 47% women). High proportions of patients considered their disease “sometimes”, “frequently” or “mostly/always” influenced leisure activities (65.1%), recreational or professional activities (57.6%), or relationships with relatives or friends (9.9%). Patients also reported that UC influenced their decision to have children (17.2%), or their ability to take care of children (40.7%); these percentages were higher in women and in younger patients. Overall, 47.0% of patients declared that UC influenced the kind of job they performed, 20.3% had rejected a job due to UC, 14.7% had lost a job due to UC, and 19.4% had had academic problems due to UC.ConclusionBeyond symptoms alone, UC imposes an enormous additional burden on patients’ social, professional, and family lives. This extra burden clearly needs to be addressed so that the ultimate goal of IBD treatment – normalization of patient quality of life – can be attained by as many patients as possible.

show abstract

“…By browsing the abstract, we obtained 69 related articles. Finally, based on the inclusion and exclusion criteria, 54 articles were excluded and 14 articles were included for analysis (Figure 1; Bandyopadhyay et al., 2015; Biedermann et al., 2019; Burisch et al., 2019; Card et al., 2016; Christodoulou et al., 2002; Felekis et al., 2009; Halling et al., 2017; Hsu et al., 2017; Isene et al., 2014; Karmiris et al., 2016; Marín‐Jiménez et al., 2014; Ozdemir et al., 2000; Park et al., 2021; Zippi et al., 2014). The 14 studies included in the meta‐analysis reported 115 854 IBD patients and 2485 IBD patients with uveitis.…”

Section: Resultsmentioning

confidence: 99%

Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta‐analysis

Lin,

Zhang,

Liang

et al. 2023

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeUveitis is one of the ocular manifestations of inflammatory bowel disease (IBD) that is often overlooked and has been considered a sign of severe IBD. As typical subtypes of IBD, differences exist in the prevalence of uveitis between Crohn's disease (CD) and ulcerative colitis (UC). Our study systematically assessed differences in the prevalence of uveitis between CD and UC.MethodsThe Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines were used. We performed a systematic review of published literature from PubMed and Embase on 30 March 2022. Two investigators independently selected studies, extracted data and evaluated methodological quality. Either a fixed‐ or a random‐effects model was used to calculate the risk ratio (RR), odds ratio (OR) and 95% confidence interval (95% CI) depending on the heterogeneity of studies. Sensitivity analysis was used to examine the heterogeneity by removing article by article, while subgroup analysis was conducted in accordance with various regions.ResultsOur study included data from 14 studies encompassing 115 854 participants. The prevalence of uveitis in IBD was estimated to be 2.38% (95% CI 1.60%–3.17%). The prevalence of uveitis in CD (3.27%, 95% CI 2.15%–4.39%) was significantly higher than in UC (1.60%, 95% CI 0.93%–2.27%; RR 1.76, 95% CI 1.39–2.22, p < 0.05). In subgroup analysis, a higher incidence of CD combined with uveitis was also observed in IBD patients residing in Europe (RR 1.75, 95% CI 1.37–2.24).ConclusionsData from 115 854 IBD patients showed that CD patients were more likely to suffer from uveitis than UC patients. Ocular manifestations in IBD, particularly CD, warrant greater attention.

show abstract

Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio Aquiles

Cited by 10 publications

References 21 publications

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain

Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta‐analysis

Contact Info

Product

Resources

About

Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio Aquiles

Cited by 10 publications

References 21 publications

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

The Gut Microbiota in Immune-Mediated Inflammatory Diseases

Patients&#39; perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain

Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta‐analysis

Contact Info

Product

Resources

About

Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain